Pepcid AC garners leading share of antacid market since June launch -- J&J/Merck.
This article was originally published in The Tan Sheet
Executive Summary
PEPCID AC SHARE OF HEARTBURN CATEGORY PEGGED AT OVER 20% by Johnson & Johnson/Merck. The company said in a Sept. 5 legal document that Pepcid AC has captured more than 20% of the $800 mil. "heartburn relief" category in "recent weeks." J&J/Merck launched the Rx-to-OTC switch H2 antagonist in June ("The Tan Sheet" June 12, p. 3).
You may also be interested in...
Singulair Switch Among Merck's OTC Possibilities
Merck may seek an OTC switch of its best-selling Singulair prescription medication, most likely asking for a nonprescription indication for allergic rhinitis
Singulair Switch Among Merck's OTC Possibilities
Merck may seek an OTC switch of its best-selling Singulair prescription medication, most likely asking for a nonprescription indication for allergic rhinitis
Singulair Switch Among Merck's OTC Possibilities
Merck may seek an OTC switch of its best-selling Singulair prescription medication, most likely asking for a nonprescription indication for allergic rhinitis